CJC-1295 monograph

CJC-1295

Overview

CJC-1295 is an investigational growth-hormone-releasing hormone analog designed to stimulate endogenous GH and downstream IGF-1 release. It is not an approved bodybuilding drug and human data are limited; most practical use in performance settings is off-label/anecdotal rather than evidence-based. The best human pharmacokinetic signal comes from the DAC/long-acting form, which produces prolonged GH/IGF-1 stimulation compared with short-acting GHRH analogs. [PubMed] [PubMed]

Pharmacokinetics & Mechanism

• Class: Investigational growth hormone-releasing hormone (GHRH) analog peptide; long-acting secretagogue variant exists with drug affinity complex (DAC)
• Mechanism of action: Acts as a GHRH receptor agonist/analog, binding the pituitary GHRH receptor to stimulate pulsatile growth hormone secretion, which then raises circulating IGF-1. The DAC formulation is designed to extend exposure by binding endogenous albumin, slowing clearance and prolonging the biologic effect. [PubMed]
• Target(s): Growth hormone-releasing hormone receptor (GHRH-R) on pituitary somatotrophs; downstream GH/IGF-1 axis (GH1, IGF1). [NCBI Gene GH1] [NCBI Gene IGF1]
• Route(s) of administration: Subcutaneous injection only in the available human literature and in community use. Oral, transdermal, and intranasal use are not established. [PubMed]
• Onset: Not well established in humans for performance use. In the published human study, GH and IGF-1 responses were measured over hours to days after injection, consistent with a rapid endocrine effect after subcutaneous dosing. [PubMed]
• Half-life: There are two clinically relevant versions: the DAC/long-acting form and the short-acting non-DAC form. In the key human study of CJC-1295 with DAC, the reported elimination half-life was approximately 5.8 to 8.1 days, while the biologic effect on GH/IGF-1 lasted about 6 days or more; without DAC, the compound is commonly described as much shorter acting, but a robust human half-life is not well established. [PubMed] [PubMed]
• Metabolism / clearance: For the DAC form, albumin binding prolongs circulation and slows proteolytic clearance; clearance is otherwise expected to follow peptide/protein catabolism, but detailed human metabolic pathways are not well established. Excretion data are not well established in humans. [PubMed]